{"id":63619,"date":"2025-04-09T03:22:24","date_gmt":"2025-04-09T03:22:24","guid":{"rendered":"https:\/?p=63619"},"modified":"2025-04-09T03:34:17","modified_gmt":"2025-04-09T03:34:17","slug":"canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/","title":{"rendered":"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals"},"content":{"rendered":"<h2 data-start=\"0\" data-end=\"277\">Cipher Pharmaceuticals (CPH:CA) (CPHRF)<\/h2>\n<p class=\"\" data-start=\"0\" data-end=\"277\"><a href=\"https:\/\/www.stocktargetadvisor.com\/Analyst-Ranking\/Canaccord-Genuity\">Canaccord Genuity<\/a> has initiated coverage of Cipher Pharmaceuticals with a &#8220;Hold&#8221; rating and a 12 month target price of <strong data-start=\"122\" data-end=\"132\">C$12.5<\/strong> per share, highlighting the potential for significant growth in the company&#8217;s revenue, driven in part by its recent acquisition of <strong data-start=\"264\" data-end=\"275\">Natroba<\/strong>.<\/p>\n<p class=\"\" data-start=\"279\" data-end=\"827\">Natroba, a topical treatment for head lice infestations, was acquired by Cipher Pharmaceuticals as part of a broader strategy to expand its product portfolio and revenue streams. The acquisition is expected to bolster Cipher\u2019s financial position by providing access to a product that has established market presence and a history of consistent demand. Additionally, Natroba is seen as a key revenue driver due to its position in the competitive dermatology market, where Cipher can leverage its existing distribution channels to grow sales further.<\/p>\n<p class=\"\" data-start=\"829\" data-end=\"1368\">The target price of <strong data-start=\"849\" data-end=\"859\">C$12.5<\/strong> reflects Canaccord Genuity&#8217;s optimism regarding Cipher\u2019s strategic acquisitions and the company&#8217;s ability to integrate new products into its portfolio. The firm believes that Cipher&#8217;s strong leadership, coupled with its ability to grow its product offerings, will continue to drive revenue growth in the coming quarters. Furthermore, the acquisition of Natroba is expected to strengthen Cipher\u2019s competitive position within the pharmaceutical industry, particularly in the dermatology and pediatrics sectors.<\/p>\n<p class=\"\" data-start=\"1370\" data-end=\"1753\">The company&#8217;s focus on developing and marketing specialized pharmaceutical products, especially in dermatology, positions it well for future growth. Given the growing demand for effective treatments in dermatological conditions, Cipher&#8217;s expanded portfolio, including Natroba, is likely to see increased market penetration, contributing to a positive revenue outlook for the company.<\/p>\n<p class=\"\" data-start=\"1755\" data-end=\"2178\"><a href=\"https:\/\/www.stocktargetadvisor.com\/\">Cipher Pharmaceuticals<\/a>&#8216; solid financials and growing product pipeline, along with the expected revenue boost from Natroba, have made it an attractive investment for analysts like Canaccord Genuity. The firm\u2019s positive stance on the stock is based on the belief that Cipher&#8217;s strategic moves will pay off, and the C$12.5 price target reflects the potential for sustained growth in the company&#8217;s market performance.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cipher Pharmaceuticals (CPH:CA) (CPHRF) Canaccord Genuity has initiated coverage of Cipher Pharmaceuticals with a &#8220;Hold&#8221; rating and a 12 month target price of C$12.5 per&#8230;<\/p>\n","protected":false},"author":3,"featured_media":63633,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-63619","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-blog","post_format-post-format-image"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Cipher Pharmaceuticals (CPH:CA) (CPHRF) Canaccord Genuity has initiated coverage of Cipher Pharmaceuticals with a &#8220;Hold&#8221; rating and a 12 month target price of C$12.5 per...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T03:22:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-09T03:34:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/04\/Screenshot-2025-04-08-233245.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1031\" \/>\n\t<meta property=\"og:image:height\" content=\"547\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals\",\"datePublished\":\"2025-04-09T03:22:24+00:00\",\"dateModified\":\"2025-04-09T03:34:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/\"},\"wordCount\":324,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/\",\"name\":\"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2025-04-09T03:22:24+00:00\",\"dateModified\":\"2025-04-09T03:34:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals","og_description":"Cipher Pharmaceuticals (CPH:CA) (CPHRF) Canaccord Genuity has initiated coverage of Cipher Pharmaceuticals with a &#8220;Hold&#8221; rating and a 12 month target price of C$12.5 per...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2025-04-09T03:22:24+00:00","article_modified_time":"2025-04-09T03:34:17+00:00","og_image":[{"width":1031,"height":547,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/04\/Screenshot-2025-04-08-233245.jpg","type":"image\/jpeg"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals","datePublished":"2025-04-09T03:22:24+00:00","dateModified":"2025-04-09T03:34:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/"},"wordCount":324,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/","name":"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2025-04-09T03:22:24+00:00","dateModified":"2025-04-09T03:34:17+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/canaccord-genuity-initiated-coverage-on-cipher-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Canaccord Genuity Initiated Coverage on Cipher Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/63619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=63619"}],"version-history":[{"count":5,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/63619\/revisions"}],"predecessor-version":[{"id":63629,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/63619\/revisions\/63629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/63633"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=63619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=63619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=63619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}